 Shares of Longeveron Inc. LGVN, 126.38 blasted 120.9 higher on very active morning trading Thursday, after the biotechnology company said its Lomecel-B for the treatment of a congenital heart defect in infants Hypoplastic Left Heart Syndrome affecting about 1,000 babies a year was granted rare pediatric disease RPD designation by the Food and Drug Administration. Trading volume exploded to 112.0 million shares, compared with the full-day average of about 110,000 shares. 